Eugenii A. Rabiner
GlaxoSmithKline Clinical Imaging Centre
London
UK
Name/email consistency: high
- Imaging the D3 receptor in humans in vivo using [11C](+)-PHNO positron emission tomography (PET). Rabiner, E.A., Laruelle, M. Int. J. Neuropsychopharmacol. (2010)
- In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice. Rabiner, E.A., Slifstein, M., Nobrega, J., Plisson, C., Huiban, M., Raymond, R., Diwan, M., Wilson, A.A., McCormick, P., Gentile, G., Gunn, R.N., Laruelle, M.A. Synapse (2009)
- Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen? Rabiner, E.A. J. Psychopharmacol. (Oxford) (2007)
- Preferential 5-HT1A autoreceptor occupancy by pindolol is attenuated in depressed patients: effect of treatment or an endophenotype of depression?. Rabiner, E.A., Bhagwagar, Z., Gunn, R.N., Cowen, P.J., Grasby, P.M. Neuropsychopharmacology (2004)
- 5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. Rabiner, E.A., Wilkins, M.R., Turkheimer, F., Gunn, R.N., Udo de Haes, J., de Vries, M., Grasby, P.M. J. Pharmacol. Exp. Ther. (2002)